Clinical Trials /

PAZOPANIB Efficacy and Tolerance in Desmoids Tumors

NCT01876082

Description:

Desmoids tumors are benign soft tissues tumors characterized by aggressiveness and potential local recurrence. There is a female predominance with a sex ratio of 2/1 and median age at diagnosis is about 30 years. Only a complete surgical excision is recommended in desmoids tumors. Some forms of desmoid tumors are recurrent and/or symptomatic and are not accessible to a conservative surgical treatment. In these clinical situations, only a medical treatment may achieve tumor control and quality of life maintenance. Place of systemic treatments in the management of desmoids tumors is poorly evaluated. Regarding chemotherapy, methotrexate and vinblastine protocol is actually the best evaluated combination, which allowed observing objective response rate between 40 and 75%. Toxicity was mainly marked by the risk of haematological toxicity. Pazopanib is an inhibitor of multi-target tyrosine kinase, in oral form, with selective type receptors -1, -2 and -3 of VEGF receptors on the PDGFA and B, and c-Kit. It is currently under clinical development in humans in the treatment of several tumor types.

Related Conditions:
  • Desmoid-Type Fibromatosis
Recruiting Status:

Completed

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
  • Official Title: PAZOPANIB Efficacy and Tolerance in Desmoids Tumors : Phase 2 Clinical Trial

Clinical Trial IDs

  • ORG STUDY ID: IB2011-03
  • NCT ID: NCT01876082

Conditions

  • Progressive Desmoids Tumors

Interventions

DrugSynonymsArms
PAZOPANIB treatmentPAZOPANIB
Active Comparator: Vinblastine and MethotrexateVinblastine and Methotrexate

Purpose

Desmoids tumors are benign soft tissues tumors characterized by aggressiveness and potential local recurrence. There is a female predominance with a sex ratio of 2/1 and median age at diagnosis is about 30 years. Only a complete surgical excision is recommended in desmoids tumors. Some forms of desmoid tumors are recurrent and/or symptomatic and are not accessible to a conservative surgical treatment. In these clinical situations, only a medical treatment may achieve tumor control and quality of life maintenance. Place of systemic treatments in the management of desmoids tumors is poorly evaluated. Regarding chemotherapy, methotrexate and vinblastine protocol is actually the best evaluated combination, which allowed observing objective response rate between 40 and 75%. Toxicity was mainly marked by the risk of haematological toxicity. Pazopanib is an inhibitor of multi-target tyrosine kinase, in oral form, with selective type receptors -1, -2 and -3 of VEGF receptors on the PDGFA and B, and c-Kit. It is currently under clinical development in humans in the treatment of several tumor types.

Detailed Description

      This is a Phase II, randomized, multicenter, open label trial, evaluating efficacy and safety
      of pazopanib versus a chemotherapy protocol combining methotrexate and vinblastine in
      progressive and symptomatic desmoid tumors.

      This study will include 72 patients in 15 centers of the French Sarcoma Group.

      Patients will be treated according to therapeutic strategy allocated by randomization until
      documented RECIST progression and for a maximum of 12 months :

        -  Arm A = experimental strategy: daily oral administration of pazopanib.

        -  Arm B = reference strategy: methotrexate-vinblastine.

      In case of documented radiological progression (RECIST criteria):

        -  Patients initially included in arm A will have the opportunity, as determined by the
           investigator, to receive arm B treatment, or leave the study,

        -  Patients initially included in arm B will have the opportunity, as determined by the
           investigator, to receive arm A treatment, or leave the study.
    

Trial Arms

NameTypeDescriptionInterventions
PAZOPANIBExperimentalPazopanib 800 mg per day oral administration at least 1 hour before or 2 hours after a meal, until disease progression or for 12 months maximum
  • PAZOPANIB treatment
Vinblastine and MethotrexateActive Comparatorvinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
  • Active Comparator: Vinblastine and Methotrexate

Eligibility Criteria

        Inclusion Criteria:

          1. Written consent;

          2. Age ≥ 18 years;

          3. ECOG ≤ 1;

          4. Histologically confirmed desmoid tumor;

          5. Disease progression before the patient's inclusion : completion of two similar imaging
             obtained within 6 months apart (a tolerance of 6 weeks is accepted)

          6. Measurable target lesion (RECIST criteria) ;

          7. Left ventricular ejection fraction (MUGA or ECHO) within the normal;

          8. Normal hematological, renal and liver functions :

               1. Hemoglobin ≥ 9 g / dl; neutrophils ≥ 1.5 x 109 / l; platelets ≥ 100 x 109 / l;
                  prothrombin time or INR1 ≤ 1.2 ULN or activated partial thromboplastin time ≤ 1.2
                  ULN;

               2. Amino alanine transferase and aspartate amino transferase ≤ 2.5 ULN;

               3. Total bilirubin ≤ 1.5 ULN;

               4. Creatinine ≤ 1.5 mg/dl or, if creatinine> 1.5 mg/dl, Creatinine clearance ≥ 50
                  m/min;

               5. Urinary protein / urinary creatinine (Pu / Cu) <1. If PU/Cu ≥ 1, patients must
                  have a proteinuria below 1g/24 h

          9. Women are eligible provided they:

               1. Physiologically incapable of childbearing (hysterectomy, oophorectomy, bilateral
                  tubal ligation, menopause).

               2. Of childbearing age if they have had a negative pregnancy test in the week before
                  the first dose of treatment.

               3. Women of childbearing potential and men must agree to take an adequate method of
                  contraception. Permitted contraceptive methods : IUD with a documented failure
                  rate of 1% per year, Partner's vasectomy, complete sex abstinence (for 14 days
                  before inclusion, the test period and after cessation of treatment according to
                  the chemotherapy as described below), dual contraception, oral contraceptives.

             Effective contraception must be implemented:

               -  Up to 6 months after treatment with vinblastine

               -  Up to 5 months after treatment with Methotrexate for men and up to 3 months after
                  treatment with Methotrexate for women

               -  For the duration of treatment with Pazopanib;

         10. Affiliated to a social security system

        Exclusion Criteria:

          1. Personal history of malignancy except:

               1. Cervical intraepithelial neoplasia;

               2. Skin basal cell carcinoma;

               3. Treated localized prostate carcinoma with PSA <1;

               4. Neoplasia treated with curative intent, in remission for at least five years and
                  considered at low risk of relapse.

          2. Pretreatement by Pazopanib or Methotrexate - vinblastine;

          3. Known allergy to Pazopanib, Methotrexate or vinblastine;

          4. Histological sampling not available for review or biological study;

          5. Clinical abnormalities which may increase the risk of gastric bleeding (not exhaustive
             list);

               1. Gastric tumor with known risk of bleeding;

               2. Inflammatory bowel disease or other gastrointestinal disease may increase the
                  risk of gastric perforation.

          6. Pathologies that can lead to impaired intestinal absorption (not exhaustive):

               1. Malabsorption;

               2. Major resection of small intestine or stomach.

          7. Active uncontrolled infectious disease;

          8. Corrected QT interval> 480 ms;

          9. History of cardiovascular disease in the last 6 months:

               1. Cardiac angioplasty;

               2. Myocardial infarction;

               3. Unstable angina;

               4. Bypass surgery;

               5. Symptomatic arterial disease.

         10. Congestive heart failure grade II, III or IV according to the New York Hearth
             Association (NYHA) classification;

         11. Uncontrolled arterial hypertension (systolic blood pressure ≥ 140 mmHg or diastolic
             blood pressure ≥ 90 mmHg);

         12. History of stroke or transient ischemic attack, pulmonary embolism or deep vein
             thrombosis not treated, within 6 months;

         13. History of major surgery or trauma within 28 days prior the first day of treatment, or
             presence of a wound, fracture or non-healed ulcer;

         14. Evidence of active bleeding or bleeding tendency;

         15. Known endobronchial lesions and / or infiltrative lesions of the large vessels lung;

         16. History of hemoptysis of more than 2.5 ml in the eight weeks preceding the first day
             of chemotherapy;

         17. Pulmonary dysfunction, asthma, emphysema, chronic obstructive pulmonary bronchitis,
             pneumonia, pneumothorax, pulmonary contusion, hemothorax, distress acute respiratory
             syndrome, pulmonary fibrosis;

         18. Severe renal dysfunction;

         19. Severe hepatic dysfunction;

         20. History of psoriasis, rheumatoid arthritis, alcoholism, illness or chronic liver
             dysfunction;

         21. Any pre-existing severe or unstable medical or psychiatric condition, or other
             condition that may interfere with patient safety, the collection of its informed
             consent or adherence to treatment;

         22. Patient who refused or could not stop taking banned drugs for at least 14 days (or 5
             half-lives of the drug) before the first day of start of chemotherapy and for the
             duration of the study;

         23. During cancer treatment:

               1. Radiotherapy, surgery or tumor embolization within 14 days before the 1st dose of
                  pazobanib (arm A) or chemotherapy methotrexate, vinblastine (arm B);

               2. Chemotherapy, immunotherapy, biological treatment, experimental or hormone
                  therapy within 14 days or 5 half-lives of medication before the first day of the
                  pazopanib (arm A) or chemotherapy with methotrexate, vinblastine (arm B).

         24. History of cancer treatment toxicity> grade 1 and / or whose the intensity increases,
             outside of alopecia.

         25. Pregnancy and lactation

         26. Concomitant treatment which can't be interrupted or replaced and which is not
             indicated with methotrexate:

               1. Probenecid (alone or associated with sulfamethoxazole),

               2. Trimethoprim,

               3. Acetylsalicylic acid (for methotrexate doses above 20 mg per week with the
                  acetylsalicylic acid and used at doses analgesics or antipyretics (≥ 500 mg per
                  dose and/or <3 g per day)or anti-inflammatory (≥ 1 g per dose and / or > 3 g per
                  day),

               4. Phenylbutazone,

               5. Yellow fever vaccine.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Efficacy evaluation in terms of non progression rate at 6 months of treatment with Pazopanib
Time Frame:6 month
Safety Issue:
Description:Non progression rate at 6 months (RECIST v.1.1, Annex I)

Secondary Outcome Measures

Measure:In each arm, efficacy evaluation in terms of best response • Progression-free survival • Overall survival Tolerance evaluation Pain assessment Quality of life evaluation Pharmacogenomic Analysis Pharmacokinetic analysis in Pazopanib arm
Time Frame:1 year
Safety Issue:
Description:Tolerance evaluation Pain assessment Quality of life evaluation Pharmacogenomic Analysis Pharmacokinetic analysis in Pazopanib arm
Measure:In each arm, efficacy evaluation in terms of progression-free survival
Time Frame:1 year
Safety Issue:
Description:
Measure:efficacy evaluation in terms of overall survival
Time Frame:1 year
Safety Issue:
Description:
Measure:Overall survival Tolerance evaluation Pain assessment Quality of life evaluation Pharmacogenomic Analysis Pharmacokinetic analysis in Pazopanib arm
Time Frame:1 year
Safety Issue:
Description:

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Institut Bergonié

Trial Keywords

  • Desmoids tumors
  • Pazopanib
  • Phase 2 clinical trial
  • Cross over

Last Updated

October 4, 2017